Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.49 |
| ▸ | PPARG | P37231 | 18/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5265449 | 0.94 | PPARG (0.52) | PPARAPPARG | |
| SCHEMBL5263781 | 0.93 | FFAR1 (0.51) | PPARAPPARGFFAR1 | |
| SCHEMBL5429046 | 0.93 | PPARA (0.44) | PPARAPPARGCYP2C9KCNH2FFAR1 | |
| SCHEMBL5264762 | 0.87 | PPARG (0.50) | PPARAPPARG | |
| SCHEMBL5229652 | 0.87 | PPARG (0.54) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL5261511 | 0.87 | PPARG (0.59) | PPARAPPARG | |
| SCHEMBL5226538 | 0.87 | PPARA (0.48) | PPARAPPARGFFAR1PPARD | |
| SCHEMBL5263903 | 0.86 | PPARG (0.48) | PPARAPPARGFFAR1 | |
| SCHEMBL5228552 | 0.86 | PPARA (0.55) | PPARAPPARG | |
| SCHEMBL5257672 | 0.86 | PPARG (0.55) | PPARAPPARGCYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | PPARA 190/4885PPARG 399/4885CYP2C9 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.